In the recent study which was held for developing new drugs against the deadly Ebola virus reported a possible therapy that could help treat patients infected with Sudan Ebola virus (SUDV).
The research was done by a team of scientist led by Sachdev Sidhu, an Indian origin, from the University of Toronto.
Not only the strain currently devastating West Africa, but also the SUDV has caused widespread illness.
During the study, the team identified an antibody directed against SUDV in mice and now they began working towards making a "humanised" version of the antibody.
For this, the team put the ebola-specific part of the mouse antibody onto a human antibody scaffold and made some changes to this molecule.
Sachdev Sidhu said, "These antibodies represent strong immuno-therapeutic candidates for the treatment of SUDV infection."
As per Sidhu and his colleagues John Dye and Jonathan Lai, about 50-90 percent of Ebola patients die after experiencing the typical symptoms of the disease, which include fever, muscle aches, vomiting and bleeding.
Among the five known ebola viruses, the Zaire (EBOV) and SUDV strains are the most deadly and cause the most recurring outbreaks.
Even many studies have focused on EBOV, the culprit of the current epidemic, however, much less attention has been placed on SUDV until now, the study concluded.